Heritable Mutations Of ALK Main Cause Of Familial Neuroblastoma - XCELLigence Cell Analysis System Useful In Cancer Research

Main Category: Cancer / Oncology
Also Included In: Pediatrics / Children's Health;  Medical Devices / Diagnostics;  Neurology / Neuroscience
Article Date: 19 Sep 2008 - 4:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Germline mutations in the anaplastic lymphoma kinase (ALK) gene explain most hereditary neuroblastomas, providing the first example of a pediatric cancer arising because of mutations in an oncogene, as a recent published research study has shown (1). Together with the reported common variations at chromosome band 6p22 predisposing to the development of sporadic neuroblastoma (2), the genetic etiology of this disease, one of the most common childhood tumors, has now being defined and has clearly established ALK as a critical neuroblastoma oncogene.

Yaël Mossé and co-workers, from Philadelphia/PA, USA, studied twenty probands with neuroblastoma and a family history of the disease (1). A total of 176 individuals (49 affected with neuroblastoma) were genotyped genome-wide. The researchers identified a significant linkage signal at chromosome bands 2p23-24 using a whole-genome scan in neuroblastoma pedigrees. Resequencing of regional candidate genes showed three separate germline missense mutations in the tyrosine kinase domain of ALK that segregated with the disease in eight separate families. Resequencing in 194 high-risk neuroblastoma samples revealed somatically acquired mutations in the tyrosine kinase domain in 12.4% of samples. Nine of the ten mutations map to critical regions of the kinase domain and were predicted, with high probability, to be oncogenic drivers. Mutations resulted in constitutive phosphorylation, and targeted knockdown of ALK messenger RNA resulted in profound inhibition of growth in all cell lines harboring mutant or amplified ALK, as well as in two out of six wild-type cell lines for ALK. The effects of siRNA knockdown on substrate adherent growth were quantified using RT-CES System, the forerunner model of the new xCELLigence cell analysis system from Roche Applied Science.

The discovery of highly penetrant, heritable ALK mutations as the cause of hereditary neuroblastoma is of immediate relevance to probands with a family history, as the researchers concluded. Screening with non-invasive techniques such as sonography and measurement of urinary catecholamine metabolites should probably be implemented for unaffected children carrying an ALK mutation. In addition, the germline or acquired activation of the cell-surface kinase provides a tractable therapeutic target for this lethal pediatric malignancy.

Roche Applied Science's xCELLigence System - originally invented as Real-Time Cell Electronic Sensing System (RT-CES®) by the US-based ACEA Biosciences and co-developed by Roche and ACEA - allows label-free dynamic monitoring of cell proliferation and viability in real-time. The technique utilizes an electronic readout of impedance to non-invasively quantify cellular status in real-time. Cells are seeded in E-Plate microtiter plates, which are integrated with microelectronic sensor arrays. The interaction of cells with the microelectrode surface generates a cell-electrode impedance response, which not only indicates cell viability but also correlates with the number of the cells seeded in the well.

http://www.xcelligence.roche.com

Literature

(1) Mossé Y et al.: Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 2008 Aug 24, Epub ahead of print

(2) Maris, JM et al.: Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med 2008; 358: 2585-2593

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at http://www.roche.com.

XCELLIGENCE is a trademark of Roche.

E-PLATE, RT-CES, and ACEA BIOSCIENCES are registered trademarks of ACEA Biosciences, Inc. in the US.

Roche